AGIO - Why Is Agios Pharmaceuticals Stock Trading Higher On Monday? | Benzinga
Shares Agios Pharmaceuticals Inc.’s (NASDAQ:AGIO) climbed after it was revealed a Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent (TD) alpha-or beta-thalassemia achieved its primary endpoint of transfusion reduction response.
Statistical significance was also achieved for all key secondary endpoints evaluating additional measures of reduction of transfusion burden compared to placebo.
The 258-patient study met its primary endpoint of transfusion reduction response: TRR, defined as a ?50% reduction in transfused red blood cell (RBC) units with a reduction of ?2 units of transfused RBCs ...